HoldsUp

Huberman Lab · 2026-06-01 · Andrew Huberman (host), Abud Bakri

Peptides: The Science, Uses & Safety | Dr. Abud Bakri

97 research-tied claims examined: 5 contradicted 5 overstated 8 context 66 supported 13 unverified

66 Supported by research
0:07:15Abud Bakrisupportedmoderate

BPC is a 40,000-dalton protein found in gastric juice, and BPC-157 is a 15-amino-acid synthetic fragment derived from it that is not naturally produced by the body.

"It's a 40,000-dalton giant peptide called BPC. BPC-157 is 15 amino acids from that giant peptide. We don't naturally make BPC-157. That's what you'll commonly hear online. We make BPC, the big protein." (said at 0:07:15)

The speaker accurately describes the origin and biochemical nature of BPC-157. Body Protection Compound (BPC) is a native ~40 kDa protein originally isolated from human gastric juice, and BPC-157 is a synthetic 15-amino-acid fragment (pentadecapeptide, sequence GEPPPGKPADDAGLV) derived from its partial sequence that does not naturally circulate on its own.

0:08:39Abud Bakrisupportedhigh

Hans Selye showed that in stressed animals, the adrenal glands enlarge, the gastric lining is damaged, and the thymus and lymphatic glands shrink.

"Hans Selye, that's coming up with the stress adaptation theory and he notices that when animals are stressed out, three things happens to them: their adrenals get really big so they make more cortisol, their gastric lining gets destroyed, and then their thymus gland and their lymphatics shrink down." (said at 0:08:39)

The speaker accurately summarizes Hans Selye's classic 1936 description of the "stress triad" (the initial stage of the general adaptation syndrome). In his landmark rodent experiments, Selye demonstrated that exposure to severe, non-specific stressors produced three hallmark pathological changes: enlargement/hyperemia of the adrenal glands, atrophy/involution of the thymus and lymphatic tissue (lymph nodes), and the formation of gastric erosions/ulcers.

0:11:02Abud Bakrisupportedvery low

In animal models, BPC-157 accelerates healing after tendon transection and ACL transection, and topically prevents gastric ulceration in burn wound models.

"They would, you know, sever tendons and then give them BPC through oral or injectable intraperitoneal administrations and they'd have faster healing times. They would sever ACL of the mice. They would do burn wounds. So when a patient has a burn wound in like the ICU, they end up having crazy gastric ulcers, but if they were able to put BPC on topically for the mouse, they would have no gastric ulcers." (said at 0:11:02)

The speaker specifically frames these findings within preclinical animal research, which is supported by published literature. Rodent studies show that BPC-157 (administered intraperitoneally, intragastrically, or topically) accelerates healing after tendon and ligament transections and prevents/attenuates burn-induced gastric ulcerations (Curling ulcers). Because this evidence base consists almost exclusively of animal experiments, certainty regarding clinical translation to humans is very low.

0:15:32Abud Bakrisupportedvery low

BPC-157 administration counteracts corticosteroid-induced impairment of wound healing in animal models.

"The other big thing that they did was they'd give corticosteroids with BPC-157 to these mice. And usually when you have a wound and you give corticosteroids, the corticosteroids will slow or even stop the wound healing from happening. When BPC was administered, the healing was either the same or even better." (said at 0:15:32)

Animal studies directly support the claim. In burned mice treated with systemic methylprednisolone, topical application of BPC-157 counteracted corticosteroid-induced impairment of burn wound healing and restored tissue repair parameters (PMID: 12781609). Similar effects have been observed in other rodent models of corticosteroid-impaired healing, including tendon-to-bone and muscle injuries (PMIDs: 16583442, 20190676). Certainty is graded as very low because the available evidence is restricted entirely to animal models.

0:16:10Abud Bakrisupportedvery low

BPC-157 increases growth hormone receptor expression in tendon tissue models.

"For example, in one tendon model, they noticed that it increased the amount of growth hormone receptors on the tendon. So theoretically, this would allow more growth hormone to dock in and cause the outgrowth of the tendon and the regrowth of it." (said at 0:16:10)

The speaker accurately described the findings of preclinical research. An in vitro study using rat Achilles tendon fibroblasts (Chang et al., 2014) demonstrated that BPC-157 upregulates growth hormone receptor mRNA and protein expression, and that subsequent stimulation with growth hormone increased cell proliferation and activated downstream JAK2 signaling. Because the evidence is limited to in vitro cellular and animal models with no clinical validation in humans, the GRADE certainty is very low.

0:16:32Abud Bakrisupportedvery low

In animal models, BPC-157 administration reduces signs of acute alcohol intoxication and prevents alcohol withdrawal symptoms.

"They also did weird things on the neurological side, like they would make these mice drunk, okay? And they would then give them BPC and they'd get less drunk when they go through mazes... And then also, they would get the mice drunk and then have them withdraw from alcohol... They got BPC and they didn't have the withdrawal symptoms." (said at 0:16:32)

The speaker specifically framed the findings as occurring in animal (mouse) models. Published preclinical rodent studies confirm that BPC-157 administration significantly opposed signs of acute alcohol intoxication (reducing duration of ethanol anesthesia, hypothermia, and motor impairment) and attenuated alcohol withdrawal manifestations (such as withdrawal-induced seizures/convulsions) following chronic alcohol exposure. Because the available evidence is restricted entirely to animal models conducted by a single laboratory group, the GRADE certainty is very low.

0:21:43Abud Bakrisupportedhigh

BPC-157 is included on the World Anti-Doping Agency (WADA) prohibited list.

"They found fragments of the 15. Like there's a paper in 2024 that looked at this and they could figure out if somebody had BPC administered for doping reasons, cuz it's on the WADA list now." (said at 0:21:43)

BPC-157 is explicitly prohibited in sport by the World Anti-Doping Agency (WADA). Effective January 1, 2022, WADA added BPC-157 to its Prohibited List under category S0 (Non-Approved Substances), which prohibits substances not approved by any governmental regulatory health authority for human therapeutic use at all times. Analytical methods and metabolic profiling studies (measuring peptide fragments/metabolites in urine via mass spectrometry) have been developed specifically to detect illicit BPC-157 administration in doping control.

0:15:39Abud Bakrisupportedvery low

BPC-157 promotes vascular endothelial growth factor (VEGF) signaling, stimulating angiogenesis and modulating nitric oxide synthesis in tissue injury models.

"Like in the models of damaging the endothelial layer or the epithelial layer of different tissues, you'll get more VEGF signaling. So that's the vascular endothelial growth factor. So you get more blood vessels, angiogenesis being formed... Downstream it'll modulate nitric oxide synthesis." (said at 0:15:39)

Preclinical in vitro and animal injury models support the claim that BPC-157 promotes vascular endothelial growth factor (VEGF/VEGFR2) signaling, stimulates endothelial tube formation and angiogenesis, and activates endothelial nitric oxide synthase (eNOS) to modulate nitric oxide production. However, evidence is currently limited to cellular and animal models, with a lack of high-quality human randomized controlled trials.

0:08:03Abud Bakrisupportedhigh

Ivan Pavlov harvested gastric juices from fistulated dogs and sold them commercially as a medicinal treatment for dyspepsia and gastric distress.

"What he'd do is he'd put a hole in the dogs' stomachs, he would feed them food and then get the gastric juices and sell that as a medicine." (said at 0:08:03)

Historical records thoroughly confirm that Ivan Pavlov and his laboratory at the Institute of Experimental Medicine in St. Petersburg surgically prepared dogs with gastric fistulas and severed esophagi (sham feeding) to collect pure gastric juice. Pavlov bottled and commercially sold this canine gastric juice across Russia and Europe as a treatment for dyspepsia and other digestive disorders, using the substantial proceeds to fund his physiological research and laboratory operations, as extensively documented in historical scholarship on Pavlov's laboratory enterprise.

0:32:17Abud Bakrisupportedhigh

Under US regulatory rules during an official drug shortage, compounding pharmacies are permitted to manufacture compounded versions of medications to meet the shortage.

"when there's a shortage of a medication, the compounders are allowed to make these drugs to meet the shortage." (said at 0:32:17)

Under US regulatory law (Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act), compounding pharmacies and outsourcing facilities are permitted to prepare compounded versions of medications when an FDA-approved drug is listed on the FDA's official Drug Shortages list, provided federal and state compounding regulations are followed.

0:39:03Abud Bakrisupportedhigh

Under FDA compounding rules, compounded medications can be prepared either during an official shortage or to meet a unique clinical need of an individual patient.

"there's two ways to get compounded medications: either a shortage or there's a unique need that the patient has." (said at 0:39:03)

The speaker's statement accurately reflects US regulatory framework under the Food, Drug, and Cosmetic Act (specifically Sections 503A and 503B as enacted and modified under the Drug Quality and Security Act). Compounded drugs generally cannot be 'essentially a copy' of an approved commercial drug unless there is a documented drug shortage on the FDA shortage list, or the medication is tailored to meet the specific clinical need of an individual patient (such as an allergy to an inactive ingredient, an altered dosage form, or a tailored strength) where an approved commercial drug is unsuitable.

0:40:53Abud Bakrisupportedhigh

In 2024, the FDA placed BPC-157 and other peptides onto the Category 2 bulk drug substances list, restricting compounding of these substances.

"because of the the move in 2024 to get these from the Category 1 to the Category 2 list and make them banned quote-unquote. That opened up this gray market zone." (said at 0:40:53)

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, the FDA evaluated bulk drug substances and placed BPC-157, alongside several other unapproved peptides (e.g., AOD-9604, CJC-1295, ipamorelin), into Category 2 of the 503A Bulk Drug Substances list. Category 2 comprises nominated substances that raise significant safety concerns and are therefore not eligible for compounding under the FDA's interim compounding policy, effectively restricting licensed compounding pharmacies from preparing them and driving consumer distribution to non-regulated research/'gray market' channels.

0:45:38Abud Bakrisupportedhigh

Development of Cardarine (GW501516) was halted because animal studies showed a signal of cancer.

"GW was a drug that was very was very promising because it had, you know, diabetic implications for metabolism and now it's a bodybuilder drug that they use for more cardio... It had a signal of cancer in animal data. So that whole thing was scrapped." (said at 0:45:38)

GW501516 (also known as Cardarine or GW1516) was investigated as a selective PPAR-delta agonist for metabolic disorders, diabetes, and cardiovascular health. Development of the compound by GlaxoSmithKline was discontinued after non-clinical rodent carcinogenicity studies revealed a dose-dependent, widespread development of tumors (cancer) across multiple organs. WADA and other regulatory/anti-doping bodies also issued safety alerts regarding its black-market use due to this carcinogenic toxicity observed in preclinical animal models.

0:45:51Abud Bakrisupportedhigh

Cardarine (GW501516) is on the World Anti-Doping Agency (WADA) prohibited list.

"Banned on on the WADA list, of course, but it had promise for treating diabetics because it changed metabolism in the liver." (said at 0:45:51)

Cardarine (GW501516 / GW1516), a PPAR-delta agonist, was added to the World Anti-Doping Agency (WADA) Prohibited List in January 2009 (originally under gene doping / non-approved substances and subsequently categorized under S4.5 Metabolic Modulators) and remains prohibited at all times in sports competition.

0:50:45Abud Bakrisupportedvery low

In mouse studies, administration of BPC-157 demonstrated protection deeper in the gastrointestinal tract against an offending agent introduced into the gut.

"And that's what they noticed in the mouse literature. They would have an offending agent into the gut and they'd notice that there would be protection deeper down in the gastric tract from that offending agent." (said at 0:50:45)

Preclinical rodent studies (predominantly in rats) evaluate the stable gastric pentadecapeptide BPC-157 against various noxious/offending agents introduced into the gastrointestinal tract (such as cysteamine, NSAIDs, and alcohol). These studies report cytoprotective effects extending deeper into the lower gastrointestinal tract, including the duodenum and colon. Because the evidence is limited to animal models—largely from a single research group—the GRADE certainty is very low.

0:52:26Andrew Huberman (host)supportedlow

Neuropod cells in the gut signal via the vagus nerve and nodose ganglion to promote or suppress dopamine release affecting food approach or avoidance behaviors.

"We had Dr. Diego Bohórquez—I can never pronounce his last name, forgive me, Diego—who's out at Duke, who's really the world expert on these neuropod cells in the gut that signal through the nodose ganglion up the vagus, nodose ganglion, to either promote or suppress release of dopamine to make you either approach or avoid certain foods." (said at 0:52:26)

Preclinical research led by Dr. Diego Bohórquez and others established that enteroendocrine 'neuropod' cells in the gut form direct, functional synapses with vagal sensory neurons (whose cell bodies reside in the nodose ganglion). These cells transduce nutrient and microbial sensory signals rapidly to the brain via glutamatergic and purinergic signaling, guiding food preferences, appetitive choices, and feeding behavior. Parallel and downstream gut-vagal neurocircuitry studies demonstrate that vagal sensory inputs project via brainstem relays to striatal and substantia nigra dopamine circuits to regulate food reinforcement and reward.

0:45:28Abud Bakrisupportedvery low

Published animal literature on BPC-157 shows no signal of increased cancer or tumorigenesis.

"There's no signal from the animal literature on BPC-157 for, you know, cancers." (said at 0:45:28)

The speaker accurately described the state of published animal research on BPC-157. Across dozens of preclinical rodent studies and systematic reviews of the animal literature, no signal of increased cancer incidence, tumor promotion, or malignant transformation has been reported. While theoretical concerns have been raised because BPC-157 promotes angiogenesis (via VEGFR2 and eNOS pathways), animal models have consistently reported favorable safety profiles without oncogenic signals, and some preclinical studies even tested for and reported anti-tumor or tumor-modulating effects. However, certainty is very low because evidence is limited entirely to animal models, largely from a single primary research network, and formal long-term rodent carcinogenicity bioassays and human oncologic safety trials are absent.

0:45:35Abud Bakrisupportedhigh

The vast majority of published animal research literature on BPC-157 originates from Dr. Predrag Sikiric's research group in Croatia.

"Now all that literature comes from one group. So we have to be very careful. That one Croatian group that tells you that it's the safest thing in the world... Dr. Sikirić is the guy behind BPC-157." (said at 0:45:35)

The speaker accurately states that the vast majority of preclinical and animal research on BPC-157 (Body Protection Compound 157) originates from Dr. Predrag Sikirić and his research team at the University of Zagreb in Croatia. Sikirić's laboratory isolated and named the peptide in the early 1990s and has authored nearly all published animal studies and reviews asserting its pleiotropic cytoprotective effects and favorable safety profile.

1:03:50Abud Bakrisupportedhigh

Di- and tripeptides can be orally bioavailable if they have the appropriate conformation and size.

"Di- and tripeptides can be orally available if they're the right shape and size." (said at 1:03:50)

The human intestinal peptide transporter PEPT1 (SLC15A1) is specifically specialized to mediate the active uptake and absorption of di- and tripeptides as well as peptide-mimetic drugs of appropriate molecular size and stereochemical conformation. This mechanism underlies both dietary oligopeptide absorption and the oral bioavailability of small peptide-like therapeutics.

1:08:29Abud Bakrisupportedlow

Pinealon is a tripeptide with the amino acid sequence Glu-Asp-Arg (EDR) that does not act via a classic known receptor.

"No known receptor. So Pinealon is a tripeptide, EDR, discovered by the aforementioned Dr. Vladimir Khavinson." (said at 1:08:29)

Pinealon is a synthetic tripeptide composed of the amino acid sequence Glu-Asp-Arg (EDR), developed by Vladimir Khavinson and colleagues. Mechanistic studies show that it penetrates cell membranes and the nucleus directly to interact with DNA, histones, and transcription regulatory pathways rather than signaling through a classical cell-surface receptor. Evidence is derived from in vitro, molecular modeling, and animal research.

1:11:08Andrew Huberman (host)supportedmoderate

Epithalon is derived from pineal gland extract, whereas Pinealon is derived from cortex extract (Cortexin).

"Epithalon is from the pineal gland. Pinealon comes from a ground-up brain extract called Cortexin." (said at 1:11:08)

The host accurately describes the origins of these peptide bioregulators. Epithalon (also known as Epitalon or peptide AEDG) is a synthetic tetrapeptide designed based on the amino acid composition of Epithalamin, a peptide extract from the bovine pineal gland (epiphysis), and was later identified directly within the pineal polypeptide complex. Pinealon (peptide EDR) is a synthetic short peptide modeled after Cortexin, a polypeptide extract derived from bovine cerebral cortex tissue.

1:11:17Abud Bakrisupportedlow

Epithalamin administration upregulates melatonin synthesis enzymes and restores melatonin production in aged monkeys and humans.

"So Khavinson identifies—he makes a drug in Russia. It's called Epithalamin, which is the pineal gland extract, and had great effect on circadian rhythmicity. And it's rich with melatonin, basically giving people melatonin, but also you upregulate the enzyme that creates melatonin from serotonin to N-acetylserotonin to melatonin. So like when he gave it to young monkeys, the monkeys had no effect, but he gave it to aged monkeys that have decreased melatonin—and you know from puberty onwards your melatonin levels dramatically decrease—he was able to restore melatonin production in these aged animals and eventually replicated it on humans." (said at 1:11:17)

The speaker accurately describes the published findings of Vladimir Khavinson and colleagues. In female rhesus monkeys (Macaca mulatta), administration of Epithalamin or its synthetic analogue Epitalon had no effect on young monkeys but significantly increased nocturnal melatonin levels in aged monkeys. Subsequent human trials by the same group showed that Epithalamin restored nighttime plasma melatonin concentrations in elderly individuals who had diminished baseline pineal activity. GRADE certainty is low because these findings originate almost exclusively from a single research group in specialized journals with limited independent replication.

1:25:17Abud Bakrisupportedhigh

Epitalon is a tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG).

"Epitalon is also AEDG, that's the amino acid, four amino acid." (said at 1:25:17)

Epitalon (also spelled Epithalon) is definitively established as a synthetic tetrapeptide consisting of four amino acids with the sequence Ala-Glu-Asp-Gly (AEDG).

1:29:26Abud Bakrisupportedhigh

Between the 1910s and 1940s, infants routinely underwent thymus irradiation to prevent sudden infant death syndrome (status thymicolymphaticus), causing thousands of subsequent cancer deaths.

"For example, like in the 1910s to 1940s, we irradiated the thymuses of young kids to prevent SIDS. This was considered gold-standard medicine... They thought that the thymus was too big and was sitting on the heart and that might be the cause. So tons of these kids, you know, I think at least 10,000 died from cancers." (said at 1:29:26)

Historical and epidemiological records confirm that from the early 1900s through the 1940s/1950s, infants and young children routinely received therapeutic X-ray irradiation of the thymus gland. The medical rationale was the misdiagnosed concept of 'status thymicolymphaticus' or 'enlarged thymus', which was believed to cause respiratory distress or sudden infant death. Subsequent long-term cohort studies (such as the Rochester thymus cohort and major pooled analyses) established that this practice caused substantial excess risks of thyroid cancer, benign thyroid neoplasms, breast cancer, leukemia, and other malignancies later in life.

1:30:37Abud Bakrisupportedmoderate

The human thymus grows from birth until puberty under the influence of hormones like melatonin, growth hormone, and DHEA, and undergoes involution after puberty.

"So the thymus is grown under the influence of a lot of these youthful hormones: melatonin, growth hormone, um DHEA, um and then is shrunk at the moment you hit puberty. So from the day of birth until puberty, you grow this massive thymus." (said at 1:30:37)

The speaker's description aligns with standard immunological and endocrinological understanding. The thymus reaches its maximum absolute mass around puberty, after which it undergoes progressive age-associated involution (characterized by adipose replacement and decreased thymopoiesis), largely triggered and accelerated by the surge in sex steroids at puberty. Growth hormone (GH) and the GH/IGF-1 axis exert trophic and regenerative effects on thymic tissue and thymopoiesis.

1:10:16Abud Bakrisupportedlow

Vladimir Khavinson isolated and sequenced specific regulatory peptides from thymus extracts, including Vilon, Thymogen, and Crystagen.

"So then he sequences from the pineal gland Epithalon, and from the thymus gland a couple different peptides—Vilon, Thymogen, Crystagen—that you'll be hearing about in the next few years, that on their own do a lot of the effects that the whole extract would do." (said at 1:10:16)

Vladimir Khavinson and his research group developed and characterized several synthetic peptide bioregulators derived from or modeled after organ extracts, including thymus-derived peptides such as Thymogen (Glu-Trp), Vilon (Lys-Glu), and Crystagen (Pro-Glu-Asp), as well as the pineal peptide Epithalon (Ala-Glu-Asp-Gly). Published research by Khavinson's team describes these short peptides mimicking specific immunomodulatory actions of crude extracts (such as Timalin). However, evidence evaluating these peptides originates almost entirely from a single research network with limited independent replication, warranting a low certainty rating for their broader clinical claims.

1:31:11Abud Bakrisupportedmoderate

Data published in the New England Journal of Medicine shows that removing residual thymus tissue during adult cardiothoracic surgery leads to an increased mortality signal within five years post-surgery.

"good data from New England Journal of Medicine that removing the thymus tissue, residue tissue leads to a mortality signal within the first five years after those surgeries." (said at 1:31:11)

A 2023 cohort study published in the New England Journal of Medicine (Kooshesh et al.) evaluated adult patients undergoing thymectomy compared to demographically matched controls undergoing cardiothoracic surgery without thymectomy. At 5 years post-surgery, all-cause mortality was significantly higher in the thymectomy group than in the control group (8.1% vs. 2.8%; relative risk, 2.9; 95% CI, 1.7 to 4.8), supporting the speaker's statement.

1:31:31Abud Bakrisupportedmoderate

Removing the thymus in adults is associated with increased incidence of cancer and autoimmune diseases.

"They'll have like either higher rates of cancers or, you know, higher rates of autoimmune diseases if they have their thymuses removed." (said at 1:31:31)

A landmark 2023 retrospective cohort study published in The New England Journal of Medicine (PMID: 37530823) evaluated 1,146 adult patients who underwent thymectomy matched to controls undergoing similar cardiothoracic surgery. At 5 years postoperatively, the thymectomy group showed a significantly increased risk of developing cancer (7.4% vs. 3.7%; relative risk 2.0, 95% CI: 1.3 to 3.2) and an increased risk of autoimmune disease among patients without preoperative infection, cancer, or autoimmunity (12.3% vs. 7.9%; relative risk 1.5, 95% CI: 1.02 to 2.2). Thymectomy was also associated with reduced T-cell production (signal joint T-cell receptor excision circles) and elevated proinflammatory cytokines.

  • supports: Health Consequences of Thymus Removal in Adults. (The New England journal of medicine 2023) · cited 184x in the literature
    "At 5 years after surgery, all-cause mortality was higher in the thymectomy group than in the control group (8.1% vs. 2.8%; relative risk, 2.9; 95% confidence interval [CI], 1.7 to 4.8), as was the risk of cancer (7.4% vs. 3.7%; relative risk, 2.0; 95% CI, 1.3 to 3.2). Although the risk of autoimmune disease did not differ substantially between the groups in the overall primary cohort (relative risk, 1.1; 95% CI, 0.8 to 1.4), a difference was found when patients with preoperative infection, cancer, or autoimmune disease were excluded from the analysis (12.3% vs. 7.9%; relative risk, 1.5; 95% CI, 1.02 to 2.2)." (abstract, results, passage verified)
    pubmedfull study (doi)
1:32:56Abud Bakrisupportedmoderate

Around age 15, the human body produces approximately 10 to the 8th naive T cells per day.

"So when you're, you know, 15, you're making uh 10 to the eighth magnitude of these cells every single day, they're called naive T cells." (said at 1:32:56)

Mathematical modeling and quantitative kinetics studies of human T-cell dynamics (combining Ki67 proliferation data, TCR excision circle [TREC] dynamics, and stable-isotope labeling) indicate that the human body generates on the order of 10^8 (hundreds of millions) naive T cells per day during adolescence and young adulthood through thymic export and homeostatic proliferation, declining gradually thereafter.

1:33:48Abud Bakrisupportedmoderate

Thymic involution starting at puberty is primarily driven by androgens, estrogens, progestins, and corticosteroids.

"So from the moment puberty starts till you die, your thymus is slowly shrinking. That really happens in your 20s and 30s, the majority of that under the the pressure of androgens, estrogens, progestins, and corticosteroids." (said at 1:33:48)

The speaker accurately describes the relationship between puberty, steroid hormones, and thymic involution. Age-related thymic atrophy accelerates noticeably during puberty, a process heavily influenced by the rise of gonadal sex steroids (androgens, estrogens, progestins) and adrenal corticosteroids (glucocorticoids). These steroid hormones induce thymocyte apoptosis and suppress thymic epithelial function; conversely, surgical or medical sex-steroid ablation (e.g., via LHRH antagonists) consistently demonstrates temporary thymic regrowth and renewed thymopoiesis. While thymic aging also involves intrinsic microenvironmental and stromal alterations (such as FOXN1 downregulation), steroid hormone signaling is established as a primary endocrine driver of post-pubertal involution.

1:35:01Abud Bakrisupportedmoderate

Castration reverses or reduces thymic involution.

"So like castration will undo some of the thymic involution." (said at 1:35:01)

The speaker's statement that castration reverses or reduces thymic involution is well supported by experimental and preclinical literature. Surgical or chemical castration (androgen deprivation) induces thymic regeneration, restoring thymic mass, cellularity, early T lineage progenitors, and thymocyte development in aged or atrophied animal models.

1:35:18Abud Bakrisupportedvery low

During pregnancy the thymus involutes, and it regrows during lactation under the influence of growth hormone and prolactin.

"They they involute and then will regrow during the breastfeeding period under the influences of growth hormone and prolactin." (said at 1:35:18)

Animal and mechanistic studies confirm that the thymus undergoes transient acute involution during pregnancy (driven by elevated sex steroids) and subsequently regenerates/recovers cellularity and function during the postpartum and lactation period. This recovery is positively regulated by neuroendocrine hormones, notably prolactin and growth hormone, which act directly on thymic epithelial cells and thymocytes.

1:35:27Abud Bakrisupportedvery low

Hibernating animals undergo marked thymic shrinkage during hibernation followed by regrowth during the feeding period.

"So hibernating animals will have a dramatic shrinkage of the thymus during hibernation and then a regrowth um during the feeding window." (said at 1:35:27)

Comparative biology and morphological studies in hibernating mammals demonstrate seasonal cyclic involution and neogenesis of the thymus gland. During autumn and winter hibernation, the thymus undergoes profound involution (characterized by tissue replacement with brown adipose tissue), followed by marked thymic regeneration/neogenesis and lymphocyte infiltration during the spring and summer active feeding period.

  • supports: [The annual involution and regeneration of the thymus in hibernating animals and perspecti… (Tsitologiia 2003) · cited 5x in the literature
    "Data on a unique phenomenon of annual involution and neogenesis of thymus gland in hibernating animals are reviewed. In accordance with morphological findings, the annual thymus involution in hibernating animals is close to the age-dependent thymus involution occurring in all mammals once in a lifetime... During hibernation, the thymus tissue is substituted by the brown fat tissue. In the spring, thymus gland neogenesis stats with intensive growth of epithelial tissue followed by lymphocyte infiltration and exhaustion of brown tissue." (abstract, passage verified)
    pubmed
1:35:44Abud Bakrisupportedvery low

In the TRIIM trial, administering growth hormone, metformin, and DHEA for 12 months increased thymic size on imaging, increased CD4 and CD8 T cells, improved their ratio, and improved T-cell exhaustion markers like PD-1.

"There's an interesting study, TRIIM trial from Dr. Greg Fahy. He's doing a study where he's giving a cocktail of growth hormone, metformin, and DHEA. Uh gave that for 12 months and had the thymic size increase on imaging. The amount of CD4 or CD8 T cells increased and the ratio of which improved. Uh and then some of the markers that would show like immune cell exhaustion, like PD-1 and all these different aspects of T-cell dynamics also improved." (said at 1:35:44)

The speaker accurately describes the published findings of the TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) pilot trial conducted by Dr. Gregory Fahy and colleagues (published in Aging Cell, 2019). In the trial, 9 healthy men (aged 51–65) received a combination of recombinant human growth hormone (rhGH), DHEA, and metformin for 12 months. The study reported MRI evidence of thymic fat replacement with functional thymic tissue (thymic regeneration), an increase in naive CD4 and CD8 T cells, improved naive-to-memory T-cell ratios, a decrease in CD8+ T-cell exhaustion markers (including PD-1 expression), and a reversal of epigenetic clock age by approximately 1.5 to 2.5 years. Because TRIIM was a small (n=9), open-label, single-arm pilot study lacking a randomized control group, the GRADE certainty for the therapeutic efficacy of this regimen is very low.

1:37:48Abud Bakrisupportedhigh

In several countries outside the US, thymosin alpha-1 is approved as an adjuvant treatment for hepatitis B, hepatitis C, and specific cancers.

"in other countries it's approved for adjuvant therapy for like hepatitis B, hepatitis C, and in different cancers." (said at 1:37:48)

The speaker's statement is accurate. Thymosin alpha-1 (synthetic form known as thymalfasin or Zadaxin) is approved in more than 30-35 countries outside the United States for indications including chronic hepatitis B virus (HBV), hepatitis C virus (HCV), and as an adjuvant/immune stimulant, including adjuvant use in chemotherapy for various cancers (such as in the Philippines and China).

1:38:08Abud Bakrisupportedhigh

Thymosin beta-4 is a 43-amino-acid peptide that modulates the cellular actin cytoskeleton and upregulates cell motility.

"Thymosin beta-4 seems to be uh this 43-amino acid peptide that helps in the actin cytoskeleton of cells. So if you think about it, immune cells have to move a lot. So they have to reorganize their actin cytoskeleton quite quickly. So it seems to upregulate that movement" (said at 1:38:08)

The speaker's statement is an accurate description of fundamental cell biology. Thymosin beta-4 (Tβ4) is well-characterized as a 43-amino-acid peptide that binds monomeric G-actin, regulates actin cytoskeleton dynamics/reorganization, and promotes cell migration and motility across various cell types.

1:42:27Abud Bakrisupportedmoderate

A recent landmark paper showed that NAD levels do not decrease in the blood over time.

"Although the paper last week says that it doesn't drop in blood, the landmark paper." (said at 1:42:27)

A landmark study published in Nature Metabolism (van de Weijer et al.) evaluated whole-blood NAD+ concentrations across seven independent human cohorts using validated ultra-high-performance liquid chromatography-mass spectrometry. The authors found that human whole-blood NAD+ levels remain stable across chronological age and do not decline with age or lifestyle interventions, directly supporting the speaker's claim.

1:46:18Abud Bakrisupportedhigh

Thymulin is a zinc-dependent nine-amino-acid peptide secreted by the thymus whose levels decline with age.

"Thymulin is a nine-amino-acid peptide that is the marker of thymus function. It also has very interesting neurological effects, which I think you'll find interesting, because it modulates what we're calling the thymus-pituitary-adrenal axis, thymus-pituitary-gonadal axis. Thymulin is this peptide that's secreted by the thymus, dramatically decreases with age, and is zinc-dependent." (said at 1:46:18)

The speaker accurately describes the biochemical and physiological properties of thymulin. Thymulin is an established zinc-dependent nonapeptide (nine-amino-acid peptide) exclusively synthesized and secreted by thymic epithelial cells. Its biological activity depends directly on binding zinc (1:1 stoichiometric complex), and circulating active levels decline markedly with age in parallel with thymic involution.

1:46:55Abud Bakrisupportedvery low

In hypophysectomized animal models, administering thymulin alongside hCG produces greater testosterone output than hCG alone.

"So they would get more testosterone produced when they got hCG with thymulin versus hCG alone." (said at 1:46:55)

Animal research in rat models directly supports this claim. Wise et al. (1998) examined testicular steroidogenesis in 5-week-old hypophysectomized rats and found that thymulin injection alone had no effect, but in hCG-primed hypophysectomized rats, administering thymulin led to significant increases in testosterone concentrations. Because the evidence is derived exclusively from preclinical rodent experiments, the GRADE certainty is very low.

1:49:09Abud Bakrisupportedmoderate

Thymulin levels decline as the first sign of zinc depletion, prior to drops in red blood cell zinc or serum zinc.

"The first sign of zinc depletion before RBC zinc or serum zinc decrease is your thymulin levels tank." (said at 1:49:09)

Published experimental human zinc depletion studies by Prasad and colleagues demonstrated that serum thymulin (a zinc-dependent thymic nonapeptide hormone) activity declines rapidly during mild zinc restriction (within 8 to 12 weeks), well before detectable reductions occur in lymphocyte zinc (20 weeks) or plasma/serum zinc concentrations (24 weeks).

1:51:45Abud Bakrisupportedhigh

GHK-Cu is a tripeptide made of glycine, histidine, and lysine complexed with copper, naturally present in type 1 collagen fibers.

"GHK-Cu is a tripeptide with a copper ion in the middle. It's glycine, histidine, and lysine. It's actually found in type 1 collagen fibers." (said at 1:51:45)

The speaker accurately describes the chemical composition and physiological occurrence of GHK-Cu. GHK is a tripeptide consisting of glycyl-L-histidyl-L-lysine that complexes with copper(II) ions, and the GHK amino acid sequence triplet occurs naturally within the alpha 2(I) chain of type 1 collagen.

1:52:12Abud Bakrisupportedlow

Serum levels of GHK-Cu drop from approximately 200 ng/mL in youth down to around 60 ng/mL by age 65.

"It's found to be very high in youth in serum levels. So you'll find this in the blood of anyone that we test, up to like 200, I think nanograms, whatever the unit was, and then gets down to like in the levels of the 60s by the age of 65." (said at 1:52:12)

Published literature on the tripeptide GHK (glycyl-L-histidyl-L-lysine) and its copper complex GHK-Cu describes human plasma levels declining from approximately 200 ng/mL in young adults (around age 20) to about 60–80 ng/mL by age 60–65. However, these specific concentrations originate from early narrative reports and small laboratory measurements by Pickart and colleagues rather than large, standardized modern cohort assays, leading to low certainty.

1:55:02Abud Bakrisupportedmoderate

Acute infections induce temporary thymic atrophy, followed by thymic regeneration during recovery.

"There's thymic atrophy that happens after every infection. The thymus kind of shrinks down, and then the idea is that you recover, you convalesce." (said at 1:55:02)

Published immunological evidence confirms that acute infections and inflammatory insults cause transient thymic atrophy (involution), which is subsequently followed by endogenous thymic repair and regeneration during convalescence to restore immune competence and T-cell production.

2:00:26Abud Bakrisupportedlow

A low lymphocyte-to-monocyte ratio on a standard complete blood count is associated with worse clinical outcomes across cardiovascular disease, cancer, and diabetes.

"If you type in any disorder—cardiovascular disease, cancer, diabetes—and put lymphocyte to monocyte ratio, there's a study that will talk about how low lymphocyte to monocyte ratio is associated with poor outcomes when it comes to that disease state." (said at 2:00:26)

Extensive observational literature and systematic reviews confirm that a lower lymphocyte-to-monocyte ratio (LMR)—or equivalently, a higher monocyte-to-lymphocyte ratio (MLR)—derived from a routine complete blood count is associated with worse clinical outcomes, including higher mortality and adverse events, across various cancers, cardiovascular diseases, and complications of diabetes. Because the underlying evidence base consists primarily of retrospective and prospective observational cohort studies, the GRADE certainty is rated as low.

2:00:47Abud Bakrisupportedmoderate

Cancer hazard risk begins to increase around an absolute lymphocyte count below 1,000 cells/µL, while a normal youthful range is 1,500 to 3,000 cells/µL.

"around 1,000 total lymphocytes is where the hazard of different cancer sites starts to increase. A young healthy person will be between 1,500 and 3,000 total lymphocytes." (said at 2:00:47)

Large prospective cohort data (such as the Copenhagen General Population Study of 108,135 participants) confirm that lymphopenia (defined clinically as lymphocyte count < 1.0–1.1 × 10^9/L or < 1,000–1,100 cells/µL) is significantly associated with an increased hazard of nonhematologic cancer death (multivariable HR 1.67) and hematologic cancer death (HR 2.79), as well as overall mortality. Standard clinical reference intervals for absolute lymphocyte count in healthy individuals typically span approximately 1.0–3.0 × 10^9/L (1,000 to 3,000 cells/µL, frequently 1,500–3,000 cells/µL in younger adults).

1:38:57Abud Bakrisupportedhigh

Allan Goldstein's laboratory isolated thymosin fraction 5 and identified thymosin alpha-1 and thymosin beta-4 from thymic tissue.

"Both thymosin alpha-1 and thymosin beta-4 come out of the Goldstein lab. That's the very famous lab that studied the thymus in the '70s, '80s, and '90s." (said at 1:38:57)

The statement accurately reflects biomedical and historical literature regarding the isolation and identification of thymosin peptides. Allan L. Goldstein and colleagues pioneered the purification of thymic extracts (thymosin fraction 5) and subsequently isolated and characterized individual active peptide components, including thymosin alpha-1 (Tα1) and thymosin beta-4 (Tβ4), during their extensive thymus research across the 1970s, 1980s, and 1990s.

1:41:08Abud Bakrisupportedhigh

Thymosin beta-4 is utilized as a doping agent in horse racing.

"Thymosin beta-4 is a very common doping agent... for the horses." (said at 1:41:08)

Thymosin beta-4 (TB4) and its synthetic derivatives (such as TB-500 / N-acetylated LKKTETQ) are well-documented illicit performance-enhancing and regenerative agents in equine sports. They are banned by the International Federation of Horseracing Authorities (IFHA), the International Federation for Equestrian Sports (FEI), and the World Anti-Doping Agency (WADA), and anti-doping laboratories have developed specialized assays to detect their misuse in racehorses.

1:51:48Abud Bakrisupportedhigh

Dr. Loren Pickart discovered the tripeptide GHK-Cu in the 1970s.

"there's an American researcher, Loren Pickart, Dr. Loren Pickart, who's passed now. He discovers GHK-Cu in the collagen tissue... He discovers it in maybe the mid-'70s." (said at 1:51:48)

The discovery of the tripeptide glycyl-L-histidyl-L-lysine (GHK / GHK-Cu) is attributed to Dr. Loren Pickart and colleagues in 1973, when it was isolated from human plasma as a growth-modulating factor. While the speaker informally refers to discovery in 'collagen tissue' in the 'mid-'70s', the core factual claim that Dr. Loren Pickart discovered the GHK/GHK-Cu peptide in the 1970s is well-documented and historically accurate.

1:53:28Abud Bakrisupportedlow

Studies by Loren Pickart comparing topical GHK-Cu to retinol and vitamin C creams demonstrated positive effects on skin remodeling.

"The Pickarts compared it to retinol and vitamin C creams and all these things with positive effects, and people anecdotally talk about their crow's feet going away and topically it does good for them." (said at 1:53:28)

Loren Pickart's publications and reviews on the human tripeptide GHK-Cu describe its positive effects on skin remodeling and repair, including reviews of comparative cosmetic evaluations against standard topical agents like vitamin C and retinol/retinoids for collagen stimulation, skin elasticity, and wrinkle reduction. However, the evidence base consists primarily of narrative reviews, in vitro/animal assays, and small cosmetic clinical evaluations, many of which were authored or summarized by Pickart.

2:06:05Abud Bakrisupportedhigh

Growth hormone is released in a circadian fashion predominantly in the first 90 minutes of slow-wave sleep.

"Growth hormone is a very circadian hormone that gets released in the first, you know, 90 minutes of slow-wave sleep." (said at 2:06:05)

Extensive human polysomnographic and endocrine studies demonstrate that growth hormone (GH) secretion is tightly linked to sleep architecture, with the primary and largest 24-hour secretory pulse occurring shortly after sleep onset during the first cycle of deep slow-wave sleep (SWS). In young healthy adults, approximately 70% of nocturnal GH pulses coincide with slow-wave sleep.

2:07:15Abud Bakrisupportedlow

Growth hormone stimulates the regrowth and regeneration of an aged, involuted thymus gland based on research by Dr. Fahy.

"We also know growth hormone is thymoregenerative because it stimulates the regrowth of an aged, involuted thymus gland based on Dr. Fahy's work." (said at 2:07:15)

The claim accurately describes the published findings of Dr. Gregory Fahy and colleagues. In 2003, Fahy published a case report demonstrating partial reversal of thymic involution and enlargement of functional thymic mass following recombinant human growth hormone (rhGH) and DHEA administration. In 2019, Fahy et al. published results from the TRIIM (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) trial (n=9 healthy men), which utilized a regimen centered on rhGH (along with DHEA and metformin) to stimulate thymic regeneration, accompanied by improvements in epigenetic age markers and immune parameters. The overall certainty is low due to small sample sizes and uncontrolled, single-arm designs.

2:08:23Andrew Huberman (host)supportedmoderate

Larger dog breeds that produce higher levels of IGF-1 downstream of growth hormone have shorter lifespans than smaller dog breeds.

"And in species like dogs where there's tremendous variation in the amount of IGF-1 that's made between, say, a Chihuahua and a Great Dane, the breed that makes more IGF-1 downstream of growth hormone, of course, lives a lot shorter lives than smaller versions of the same species." (said at 2:08:23)

Comparative canine biology and aging research confirm that larger dog breeds exhibit higher circulating levels of insulin-like growth factor 1 (IGF-1) and significantly shorter lifespans compared to small dog breeds. Observational studies assessing serum IGF-1 across diverse purebred and mixed-breed dogs show an overall positive correlation between body weight and IGF-1 levels, in line with the well-established inverse relationship between breed size and lifespan in domestic dogs.

2:10:31Abud Bakrisupportedhigh

Growth hormone promotes the conversion of T4 to T3.

"growth hormone favors the conversion of T4 to T3, so it changes the thyroid dynamics." (said at 2:10:31)

Human clinical trials and mechanistic studies consistently demonstrate that growth hormone (GH) administration stimulates the peripheral conversion of thyroxine (T4) to active triiodothyronine (T3), resulting in decreased circulating free T4 / reverse T3 and increased circulating free T3 levels.

2:12:20Abud Bakrisupportedhigh

Growth hormone and growth hormone secretagogues reduce insulin sensitivity and can elevate HbA1c levels.

"growth hormone and secretagogues have a negative effect on insulin sensitivity, right? So people's A1Cs will usually jump." (said at 2:12:20)

Exogenous growth hormone (GH) and GH secretagogues (such as MK-677/ibutamoren) exert counter-regulatory, anti-insulin actions. Randomized controlled trials and clinical reviews consistently demonstrate that administration of GH or GH secretagogues reduces peripheral insulin sensitivity, impairs glucose tolerance, and increases circulating blood glucose and glycemic markers.

2:23:25Abud Bakrisupportedhigh

Modern GLP-1 receptor agonist medications, including retatrutide, can produce 10% to 30% body weight loss in patients.

"Now with the GLP-1s, we're getting 10, 20, even 30% of body weight being shaved off of people, especially with the new retatrutide data." (said at 2:23:25)

Randomized clinical trials confirm that modern GLP-1 receptor agonists and multi-incretin agonists (such as dual GIP/GLP-1 agonist tirzepatide and triple GIP/GLP-1/glucagon agonist retatrutide) produce mean weight reductions spanning roughly 10% to over 24%, with substantial proportions of patients achieving 20% to 30% or more body weight loss. In a phase 2 trial of retatrutide in adults with obesity, the mean weight loss at 48 weeks reached 24.2% at the 12 mg dose, with 83% achieving at least 15% weight loss. Similarly, in the SURMOUNT-1 trial of tirzepatide, mean weight loss was up to 20.9% at week 72, with 57% of participants in the 15-mg group achieving a reduction of 20% or more.

2:24:44Abud Bakrisupportedhigh

Natural GLP-1-like compound exendin-4 was discovered in the saliva of the Gila monster.

"this is another animal-derived compound, right? It's found in the saliva of the Gila monsters." (said at 2:24:44)

The claim is fully supported. Exendin-4 is a naturally occurring 39-amino-acid peptide originally isolated from the venom/salivary secretions of the Gila monster (*Heloderma suspectum*). It acts as a glucagon-like peptide-1 (GLP-1) receptor agonist and served as the basis for the synthetic GLP-1 receptor agonist drug exenatide (Byetta).

2:29:56Abud Bakrisupportedmoderate

Published literature shows that GLP-1 receptor agonists reduce alcohol cravings.

"And we know the literature shows that people now are having less alcohol cravings from this." (said at 2:29:56)

Published clinical literature, including randomized controlled trials and systematic reviews/meta-analyses, shows that GLP-1 receptor agonists (specifically semaglutide) significantly reduce alcohol cravings and consumption in individuals with alcohol use disorder or hazardous drinking patterns.

2:15:10Andrew Huberman (host)supportedhigh

Retatrutide is a multi-agonist targeting GLP-1, GIP, and glucagon receptor pathways.

"retatrutide is hitting things other than the GLP pathway. It's also GIP and glucagon pathway" (said at 2:15:10)

Retatrutide (LY3437943) is an engineered single-peptide triple receptor agonist designed to activate the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, as confirmed in pharmacological characterizations and randomized clinical trials.

2:14:28Abud Bakrisupportedhigh

MK-677 (ibutamoren) is a non-peptide growth hormone secretagogue and ghrelin receptor agonist.

"MK is not a peptide; it's a non-peptide GHRP." (said at 2:14:28)

MK-677 (also known as ibutamoren or MK-0677) is an orally active, non-peptide growth hormone secretagogue that acts as an agonist at the growth hormone secretagogue receptor (GHSR / ghrelin receptor).

2:32:56Abud Bakrisupportedhigh

The standard starting dose of Ozempic (semaglutide) is 0.25 mg, escalating to 0.5 mg.

"You start at 0.25 and escalate to 0.5." (said at 2:32:56)

The standard label-recommended initiation and dose-escalation schedule for subcutaneous semaglutide (Ozempic) begins at 0.25 mg once weekly for 4 weeks (to minimize gastrointestinal side effects) before escalating to 0.5 mg once weekly. This titration schedule is standard across clinical trial protocols and regulatory prescribing information.

2:33:16Abud Bakrisupportedhigh

In non-diabetics, blood sugar levels do not drop very low when taking GLP-1 receptor agonists.

"The blood sugar effect for non-diabetics don't get that low" (said at 2:33:16)

The claim is supported. GLP-1 receptor agonists stimulate insulin secretion and inhibit glucagon release in a glucose-dependent manner; as blood glucose levels decrease toward normal physiological levels, their insulinotropic effect ceases, intrinsically limiting the risk of severe hypoglycemia in non-diabetic individuals receiving them for weight management.

2:35:46Andrew Huberman (host)supportedhigh

Human chorionic gonadotropin (hCG) is commonly prescribed to restore fertility in men and is mostly given during IVF cycles in women.

"So hCG, human chorionic gonadotropin, this is commonly prescribed for trying to restore fertility to men, but it's mostly being given in IVF cycles to women." (said at 2:35:46)

Human chorionic gonadotropin (hCG) is an established therapeutic agent in reproductive medicine for both men and women. In men, hCG acts as a luteinizing hormone (LH) analog to stimulate Leydig cells, boost intratesticular testosterone, and induce or restore spermatogenesis in cases of hypogonadotropic hypogonadism or steroid-induced infertility. In women, hCG is extensively used in assisted reproductive technology (ART) and in vitro fertilization (IVF) cycles as a 'trigger' for final oocyte maturation prior to retrieval.

2:36:30Abud Bakrisupportedhigh

Orforglipron is a non-peptide GLP-1 receptor agonist.

"orforglipron, which is not a peptide, but still GLP-1 agonist" (said at 2:36:30)

Orforglipron is a small-molecule, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist developed as an oral once-daily therapy for type 2 diabetes and obesity.

2:39:35Abud Bakrisupportedhigh

There are no published animal or human studies or case reports on the effects of BPC-157 in endometriosis or fibroids.

"No literature exists on either animal or human data that relates to those peptides... there's no case reports or studies that would suggest positive or negative." (said at 2:39:35)

A systematic search of biomedical literature databases (PubMed and Europe PMC) for BPC-157 (and its synonyms) combined with terms for endometriosis, uterine fibroids, leiomyoma, or myoma returns zero results. Recent comprehensive reviews of BPC-157 confirm that preclinical research has been confined largely to musculoskeletal, gastrointestinal, and ischemia-reperfusion models, and that human clinical evidence is limited to a few small pilot studies in unrelated indications (e.g., knee pain, interstitial cystitis). Thus, the speaker's assertion that no animal or human studies or case reports exist regarding BPC-157 in endometriosis or fibroids is accurate.

2:40:36Abud Bakrisupportedhigh

Russian studies have evaluated Cortexin and Cerebrolysin for traumatic brain injury (TBI).

"Yeah, there were studies in Russia on TBI when it comes to Cortexin and Cerebrolysin" (said at 2:40:36)

Numerous clinical studies published in Russian medical journals (such as Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova) have evaluated the efficacy and neurotrophic effects of both Cortexin and Cerebrolysin in patients recovering from acute and long-term traumatic brain injury.

2:40:52Abud Bakrisupportedvery low

In mouse data, BPC-157 attenuates alcohol intoxication and alcohol withdrawal.

"The mice can't get too drunk, and they can't withdraw from alcohol." (said at 2:40:52)

Published rodent studies specifically demonstrate that BPC-157 attenuates both acute alcohol intoxication (reducing ethanol-induced anesthesia, hypothermia, and mortality) and withdrawal symptoms (reducing withdrawal seizures) in mice. However, this evidence is entirely preclinical and limited to animal models from a single research group, yielding very low certainty for human clinical application.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.